PATIENT PERSPECTIVES ON POST-VACCINATION SIDE EFFECTS FOLLOWING INFLUENZA, COVID-19, OR RESPIRATORY SYNCYTIAL VIRUS VACCINATION: EVIDENCE FROM CONJOINT ANALYSES IN A TARGETED LITERATURE REVIEW
Author(s)
Sarolta Borbely, MSc1, Jose Luis Bartelt Hofer, PhD2.
1Sanofi, Budapest, Hungary, 2Global Director HE&OR Vaccines, Sanofi Vaccines, Lyon, France.
1Sanofi, Budapest, Hungary, 2Global Director HE&OR Vaccines, Sanofi Vaccines, Lyon, France.
OBJECTIVES: Post-vaccination side effects (PVSE) are frequently included as key attribute in vaccine conjoint analyses (CA), mostly discrete choice experiments; this sub‑analysis of a targeted literature review (TLR) examines its ways of inclusion, weight and trade-offs when presented as an attribute for influenza, respiratory syncytial virus (RSV), or COVID‑19 vaccinations.
METHODS: A PubMed‑based TLR (November 2025) identified CA using disease‑specific and preference‑methodology keywords. Hybrid manual and AI‑assisted screening and extraction with dual‑reviewer quality checks were performed. PVSE‑related preference insights were synthesized; additional TLR findings are reported elsewhere.
RESULTS: Out of 2730 identified, 34/38 eligible records included at least one PVSE attribute: any severity (n=11), mild (n=22) and/or severe (n=21). Most of eligible CA were done for COVID-19 vaccines (n=32), followed by influenza (n=6) and RSV (n=1). After vaccine efficacy/effectiveness, PVSE ranked the 2nd most important attribute of a vaccine. Relative to other attributes, the weight of PVSE is 2% to 43% in the vaccine choice (middle range 17% to 28%). While individuals are willing to accept some risk for higher protection, there’s a very low tolerance for serious PVSE. A study found that a 10% additional risk of mild PVSE could reduce the chances of choosing the vaccine by 14%. Among subgroups, studies report broadly directionally similar preferences for vaccine-hesitant individuals (relative to the fully vaccinated) and the elderly, who prioritize avoiding severe PVSE and give more weight to mild ones.
CONCLUSIONS: This research highlights PVSE as the second most influential attribute in vaccines for three common respiratory diseases. Findings suggest that patient preferences are highly sensitive to PVSE severity, with particularly low tolerance for severe PVSE and meaningful trade‑offs even for mild ones. These results underscore the importance of incorporating granular PVSE severity categorization in CA to accurately capture patient preferences and inform vaccine design and communication strategies.
METHODS: A PubMed‑based TLR (November 2025) identified CA using disease‑specific and preference‑methodology keywords. Hybrid manual and AI‑assisted screening and extraction with dual‑reviewer quality checks were performed. PVSE‑related preference insights were synthesized; additional TLR findings are reported elsewhere.
RESULTS: Out of 2730 identified, 34/38 eligible records included at least one PVSE attribute: any severity (n=11), mild (n=22) and/or severe (n=21). Most of eligible CA were done for COVID-19 vaccines (n=32), followed by influenza (n=6) and RSV (n=1). After vaccine efficacy/effectiveness, PVSE ranked the 2nd most important attribute of a vaccine. Relative to other attributes, the weight of PVSE is 2% to 43% in the vaccine choice (middle range 17% to 28%). While individuals are willing to accept some risk for higher protection, there’s a very low tolerance for serious PVSE. A study found that a 10% additional risk of mild PVSE could reduce the chances of choosing the vaccine by 14%. Among subgroups, studies report broadly directionally similar preferences for vaccine-hesitant individuals (relative to the fully vaccinated) and the elderly, who prioritize avoiding severe PVSE and give more weight to mild ones.
CONCLUSIONS: This research highlights PVSE as the second most influential attribute in vaccines for three common respiratory diseases. Findings suggest that patient preferences are highly sensitive to PVSE severity, with particularly low tolerance for severe PVSE and meaningful trade‑offs even for mild ones. These results underscore the importance of incorporating granular PVSE severity categorization in CA to accurately capture patient preferences and inform vaccine design and communication strategies.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
PCR207
Topic
Clinical Outcomes, Medical Technologies, Patient-Centered Research
Topic Subcategory
Patient Behavior and Incentives
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Vaccines